GT Biopharma Inc (GTBP)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
| 06-2012 | 03-2012 | 12-2011 | 09-2011 | 06-2011 | |
| Assets | |||||
| Current Assets | |||||
| Cash & Cash Equivalents | 5 | 120 | 92 | 0 | 89 |
| Inventories | 92 | 12 | 12 | N/A | N/A |
| TOTAL | $109 | $144 | $104 | $343 | $194 |
| Non-Current Assets | |||||
| Intangibles | 16 | 22 | 25 | 28 | 34 |
| TOTAL | $16 | $22 | $25 | $28 | $34 |
| Total Assets | $125 | $166 | $129 | $371 | $228 |
| Liabilities | |||||
| Current Liabilities | |||||
| Short Term Debt | 1,930 | 1,937 | 1,770 | 1,644 | 1,867 |
| Accounts payable and accrued liabilities | 813 | 815 | 806 | 974 | 772 |
| Accrued Expenses | 3,027 | 2,111 | 2,205 | 2,171 | 1,952 |
| Other current liabilities | 514 | 303 | 158 | 290 | 980 |
| TOTAL | $6,559 | $5,429 | $5,230 | $5,277 | $5,798 |
| Non-Current Liabilities | |||||
| TOTAL | $N/A | $N/A | $N/A | $N/A | $N/A |
| Total Liabilities | $6,559 | $5,429 | $5,230 | $5,277 | $5,798 |
| Shareholders' Equity | |||||
| Shares Outstanding, K | 364,300 | 329,799 | 300,300 | 238,623 | 215,423 |
| Common Shares | 364 | 300 | 269 | 239 | 209 |
| Retained earnings | -86,805 | -84,410 | -83,795 | -82,657 | -82,680 |
| Other shareholders' equity | -10 | 3 | 3 | 3 | 3 |
| TOTAL | $-6,434 | $-5,263 | $-5,101 | $-4,906 | $-5,570 |
| Total Liabilities And Equity | $125 | $166 | $129 | $371 | $228 |